The burden of depressive symptoms in the long-term treatment of patients with schizophrenia

Schizophr Res. 2007 Feb;90(1-3):186-97. doi: 10.1016/j.schres.2006.09.027. Epub 2006 Nov 15.

Abstract

Objective: To prospectively measure the link between depressive symptoms and functional outcomes in the long-term treatment of people with schizophrenia.

Methods: Data were drawn from a large, multi-site, 3-year, prospective, naturalistic, observational study, in which subjects with schizophrenia were assessed at enrollment and at 12-month intervals thereafter. Individuals who were "Depressed" (defined as a total score > or =16 on the Montgomery-Asberg Depression Rating Scale) at enrollment were compared to those "Non-depressed" on functional outcomes, using self-report measures, clinicians' ratings, and information from medical records. Statistical analyses included Generalized Estimation Equation and mixed regression analyses adjusted for individual characteristics. Longitudinal group comparisons across the 3-year study were augmented with a cross-sectional group comparison at enrollment.

Results: At enrollment, 39.4% (877/2228) of the participants were deemed Depressed. Across the 3-year study, the depressed cohort was significantly more likely than the Non-depressed to use relapse-related mental health services (emergency psychiatric services, sessions with psychiatrists); to be a safety concern (violent, arrested, victimized, suicidal); to have greater substance-related problems; and to report poorer life satisfaction, quality of life, mental functioning, family relationships, and medication adherence. Furthermore, changes in depressed status were associated with changes in functional outcomes.

Conclusions: People with schizophrenia and concurrent depressive symptoms have poorer long-term functional outcomes compared to the Non-depressed. Their poorer quality of life, greater use of mental health services, and higher risk of involvement with law enforcement agencies underscore a need for special treatment interventions. Treatment of the non-psychotic dimensions of schizophrenia is a critical part of recovery.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activities of Daily Living / psychology
  • Adult
  • Antipsychotic Agents / therapeutic use*
  • Comorbidity
  • Cost of Illness*
  • Depression / diagnosis*
  • Depression / drug therapy*
  • Depression / epidemiology
  • Depression / psychology
  • Drug Therapy, Combination
  • Dyskinesia, Drug-Induced / diagnosis
  • Dyskinesia, Drug-Induced / psychology
  • Female
  • Humans
  • Long-Term Care
  • Male
  • Mental Health Services / statistics & numerical data
  • Middle Aged
  • Prospective Studies
  • Psychotic Disorders / diagnosis*
  • Psychotic Disorders / drug therapy*
  • Psychotic Disorders / epidemiology
  • Psychotic Disorders / psychology
  • Quality of Life / psychology
  • Recurrence
  • Schizophrenia / diagnosis*
  • Schizophrenia / drug therapy*
  • Schizophrenia / epidemiology
  • Schizophrenic Psychology*
  • United States
  • Utilization Review / statistics & numerical data

Substances

  • Antipsychotic Agents